Construction of recombinant eukaryotic expression plasmid containing murine CD40 ligand gene and its expression in H22 cells

World Journal of Gastroenterology

Volumn 11, Issue 2, 2005, Pages 182-186

  Jiang, Yong Fang ^a   He, Yan ^a   Gong, Guo Zhong ^a   Chen, Jun ^a   Yang, Chun Yan ^a   Xu, Yun ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Genetic vectors; Hepatocellular carcinoma; Murine CD40 ligand; Plasmids

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; COMPLEMENTARY DNA; RESTRICTION ENDONUCLEASE;

ANIMAL CELL; ANTIGEN BINDING; ANTIGEN PRESENTING CELL; ARTICLE; CELL ACTIVATION; CELL MEMBRANE; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA INTEGRATION; DNA SYNTHESIS; ELECTROPHORESIS; ENZYME DEGRADATION; EUKARYOTE; EXPRESSION VECTOR; FEMALE; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC TRANSFECTION; HUMORAL IMMUNITY; IMMUNOFLUORESCENCE; LIVER CELL CARCINOMA; MOLECULAR CLONING; MOUSE; NONHUMAN; PLASMID; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TUMOR IMMUNITY;

EID: 12344304161     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i2.182     Document Type: Article

References (36)

1. Tang ZY. Hepatocellular carcinoma-Cause, treatment and metastasis. World J Gastroenterol 2001; 7: 445-454
2. Mach F, Schonbeck U, Sukhova GK, Bourcier T, Bonnefoy JY, Pober JS, Libby P. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 1997; 94: 1931-1936
3. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998; 16: 111-135
4. Roy M, Waldschmidt T, Aruffo A, Ledbetter JA, Noelle RJ. The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+ T cells. J Immunol 1993; 151: 2497-2510
5. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T- killer cell. Nature 1998; 393: 474-478
6. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998; 393: 478-480
7. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998; 393: 480-483
8. Schmitz V, Barajas M, Wang L, Peng D, Duarte M, Prieto J, Qian C. Adenovirus-mediated CD40 ligand gene therapy in a rat model of orthotopic hepatocellular carcinoma. Hepatology 2001; 34: 72-81
9. Miyazaki M, Ito H, Nakagawa K, Shimizu H, Yoshidome H, Shimizu Y, Ohtsuka M, Togawa A, Kimura F. An approach to intrapericardial inferior vena cava through the abdominal cavity, without median sternotomy, for total hepatic vascular exclusion. Hepatogastroenterology 2001; 48: 1443-1446
10. Mazzanti R, Giallombardo AL, Mini E, Nobili S, Neri B, Arena U, Pantaleo P, Fabbroni V, Ghilardi M, Gattai R, Bandettini L. Treatment of locally advanced hepatocellular carcinoma by hepatic intra-artery chemotherapy: a pilot study. Dig Liver Dis 2004; 36 278-285
11. Qian GJ, Chen H, Wu MC. Percutaneous cryoablation after chemoembolization of liver carcinoma: report of 34 cases. Hepatobiliary Pancreat Dis Int 2003; 2: 520-524
12. Chen WT, Chau GY, Lui WY, Tsay SH, King KL, Loong CC, Wu CW. Recurrent hepatocellular carcinoma after hepatic resection: prognostic factors and long-term outcome. Eur J Surg Oncol 2004; 30: 414-420
13. Ruiz J, Mazzolini G, Sangro B, Qian C, Prieto J. Gene therapy of hepatocellular carcinoma. Dig Dis 2001; 19: 324-332
14. Chouaib S, Asselin-Paturel C, Mami-Chouaib F, Caignard A, Blay JY. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today 1997; 18: 493-497
15. Gabrilovich DI, Chen HL, Girgis KP, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D, Carbone DP. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2: 1096-1103
16. Ruiz J, Qian C, Drozdzik M, Prieto J. Gene therapy of viral hepatitis and hepatocellular carcinoma. J Viral Hepat 1999; 6: 17-34
17. Melero I, Mazzolini G, Narvaiza I, Qian C, Chen L, Prieto J. IL-12 gene therapy for cancer: in synergy with other immunotherapies. Trends Immunol 2001; 22: 113-115
18. Bullens DM, Kasran A, Thielemans K, Bakkus M, Ceuppens JL. CD40L-induced IL-12 production is further enhanced by the Th2 cytokines IL-4 and IL-13. Scand J Immunol 2001; 53: 455-463
19. Harada M, Tamada K, Abe K, Yasumoto K, Kimura G, Nomoto K. Role of the endogenous production of interleukin 12 in immunotherapy. Cancer Res 1998; 58: 3073-3077
20. Ottaiano A, Pisano C, De Chiara A, Ascierto PA, Botti G, Barletta E, Apice G, Gridelli C, Iaffaioli VR. CD40 activation as potential tool in malignant neoplasms. Tumori 2002; 88: 361-366
21. Sotomayor EM, Borrello I, Tubb E, Rattis FM, Bien H, Lu Z, Fein S, Schoenberger S, Levitsky HI. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med 1999; 5: 780-787
22. Diehl L, den Boer AT, Schoenberger SP, ven der Voort EI, Schumacher TN, Melief CJ, Offringa R, Toes RE. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med 1999; 5: 774-779
23. Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 2000; 96: 2917-2924
24. Wendtner CM, Kofler DM, Theiss HD, Kurzeder C, Buhmann R, Schweighofer C, Perabo L, Danhauser-Riedl S, Baumert J, Hiddemann W, Hallek M, Buning H. Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors. Blood 2002; 100: 1655-1661
25. von Bergwelt-Baildon M, Maecker B, Schultze J, Gribben JG. CD40 activation: potential for specific immunotherapy in B-CLL. Ann Oncol 2004; 15: 853-857
26. Saudemont A, Buffenoir G, Denys A, Desreumaux P, Jouy N, Hetuin D, Banters F, Fenaux P, Quesnel B. Gene transfer of CD154 and IL12 cDNA induces an anti-leukemic immunity in a murine model of acute leukemia. Leukemia 2002; 16: 1637-1644
27. Noguchi M, Imaizumi K, Kawabe T, Wakayama H, Horio Y, Sekido Y, Hara T, Hashimoto N, Takahashi M, Shimokata K, Hasegawa Y. Induction of antitumor immunity by transduction of CD40 ligand gene and interferon-gamma gene into lung cancer. Cancer Gene Ther 2001; 8 421-429
28. Tada Y, O-Wang J, Yu L, Shimozato O, Wang YQ, Takiguchi Y, Tatsumi K, Kuriyama T, Takenaga K, Sakiyama S, Tagawa M. T-cell-dependent antitumor effects produced by CD40 ligand expressed on mouse lung carcinoma cells are linked with the maturation of dendritic cells and secretion of a variety of cytokines. Cancer Gene Ther 2003; 10: 451-456
29. Sun Y, Peng D, Lecanda J, Schmitz V, Barajas M, Qian C, Prieto J. In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity. Gene Ther 2000; 7 1467-476
30. Buning C, Kruger K, Sieber T, Schoeler D, Schriever F. Increased expression of CD40 ligand on activated T cells of patients with colon cancer. Clin Cancer Res 2002; 8: 1147-1151
31. Loskog A, Totterman TH, Bohle A, Brandau S. In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154. Cancer Gene Ther 2002; 9 846-853
32. Loskog A, Bjorkland A, Brown MP, Korsgren O, Malmstrom PU, Totterman TH. Potent antitumor effects of CD154 transduced tumor cells in experimental bladder cancer. J Urol 2001; 166: 1093-1097
33. Hussain SA, Ganesan R, Hiller L, Murray PG, el-Magraby MM, Young L, James ND. Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder. Br J Cancer 2003; 88: 586-592
34. Peter I, Naweath M, Kamarashev J, Odermatt B, Mezzacasa A, Hemmi S. Immunotherapy for murine K1735 melanoma: combinatorial use of recombinant adenovirus expressing CD40L and other immunomodulators. Cancer Gene Ther 2002; 9: 597-605
35. Friedlander PL, Delaune CL, Abadie JM, Toups M, LaCour J, Marrero L, Zhong Q, Kolls JK. Efficacy of CD40 ligand gene therapy in malignant mesothelioma. Am J Respir Cell Mol Biol 2003; 29 3Pt 1): 321-330
36. Yanagi K, Nagayama Y, Nakao K, Saeki A, Matsumoto K, Ichikawa T, Ishikawa H, Hamasaki K, Ishii N, Eguchi K. Immuno-gene therapy with adenoviruses expressing fms-like tyrosine kinase 3 ligand and CD40 ligand for mouse hepatoma cells in vivo. Int J Oncol 2003; 22: 345-351